Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05635708 · ClinicalTrials.gov registry record · Phase 2
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer, sponsored by BeiGene.
- Active
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT05635708 is a Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 400 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05635708, a Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Tislelizumab
- DRUG LBL-007
- DRUG BGB-A445
Study Locations (20)
Other
- Hospital de Amor Barretos - Barretos
- Hospital Do Cancer de Londrina - Londrina
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus - Porto Alegre
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto - São José do Rio Preto
- Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira - São Paulo
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
- Chris Obrien Lifehouse - Camperdown
- Northern Beaches Hospital - Frenchs Forest
- Port Macquarie Base Hospital - Port Macquarie
Western Australia
- One Clinical Research - Nedlands
- St John of God Health Care - Subiaco
California
- Valkyrie Clinical Trials - Los Angeles
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Memorial Sloan Kettering Cancer Center Mskcc - New York
Oregon
- Providence Portland Medical Center - Portland
Texas
- The University of Texas Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05635708
The ClinicalTrials.gov registry entry for NCT05635708 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (39% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05635708 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New South Wales, Western Australia.
Frequently Asked Questions
What is clinical trial NCT05635708 about?
NCT05635708 is a clinical study titled "A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer". The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung can...
What is the current status of trial NCT05635708?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2023-03-07. Estimated completion is 2026-10.
What conditions does trial NCT05635708 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT05635708?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Tislelizumab (DRUG), LBL-007 (DRUG), BGB-A445 (DRUG).
Who is sponsoring clinical trial NCT05635708?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05635708 being conducted?
This trial has 20 study locations across California, Massachusetts, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Non-Small Cell Lung Cancer
All registered trials for this condition
Metastatic Non Small Cell Lung Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.